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The BRAF gene is the most frequently mutated gene in 
malignant melanoma (MM). When mutated, it is associated 
with a more aggressive disease phenotype. MicroRNAs (miRs) 
are small non-coding RNAs that downregulate the expression 
of their target genes by binding to their 3′-UTR. 
 
 
 
 
 
 
 
 
 
 
Recently, microRNA miR-3151 was identified in intron 1 of 
BAALC, the most upregulated gene in BRAF mutated 
(BRAFmut) MM. In acute myeloid leukemia, both high miR-
3151 and high BAALC are associated with poor survival. In 
addition, miR-3151 has leukemogenic activity via direct 
deregulation of TP53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We hypothesized that miR-3151 is deregulated in MM and 
leads to deregulation of the TP53 apoptosis pathway. 
Furthermore, we hypothesized that miR-3151 expression may 
be increased by BRAF mutations and may contribute to the 
increased disease aggressiveness of BRAFmut MM. 
 
 
 
Introduction Methods  
Stable miR-3151 expression: To stably express miR-3151 
in MM cell lines (A375, Mel-39, MeWo), we used the miR-
3151 hairpin sequence with 200 bp flanking sequence 
cloned into a HIV-based lentiviral expression vector.  
Quantifying TP53 expression: To assess the effects of 
forced miR-3151 expression on TP53 expression, RNA was 
harvested 12h after infection of MM cell lines (A375, MeWo) 
and TP53 expression was determined using quantitative 
PCR (qPCR) to quantify RNA expression. 
In addition, protein was harvested 24h after infection and 
TP53 expression was analyzed using Western blots. 
 
 
 
 
Gene expression manipulation: siRNA-mediated 
knockdown was used to silence BRAF in BRAFmut MM cell 
lines (A375, Mel-39). miR-3151 and TP53 expression was 
determined using qPCR.  
Furthermore, we transfected the BRAF wild-type (BRAFwt) 
cell line (MeWo) with plasmids containing either the 
BRAFwt or BRAFmut vectors. 
 
 
 
 
 
 
Caspase-3/7 Chemiluminescent assays: We performed 
caspase-3/7GLO assays with miR-3151 or antagomiR-3151 
infected MM cell lines (A375, Mel-39) to see a change in 
apoptosis rates caused by expression manipulation of miR-
3151.  
Flow cytometry: Flow cytometry was used to distinguish 
which phase cells were undergoing in the cell cycle (G1, S, 
G2) in an antagomiR-3151 infected MM cell line (Mel-39) 
compared to scramble control.  
 
 
 
 
Future directions 
Next steps: 1) To see if other BRAF mutated 
malignancies (papillary thyroid cancer) have increased 
miR-3151 expression. 
2) To see if the efficacy of Vemurafenib is increased 
when used in conjunction with the antagomiR-3151 
virus in MM. 
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Results 
Figure 8: miR-3151 and BAALC 
expression levels were determined in 
20 MM patient samples. The BRAF 
mutation status was then 
determined. BRAFmut patients had a 
5-fold higher miR-3151 expression 
compared to BRAFwt patients. 
Figure 5: (A) miR-3151 and TP53 expression were determined in 20 MM patients. 
Patients with high miR-3151 expression had lower TP53 expression. miR-3151 was 
overexpressed in MM cell lines. Forced expression of miR-3151 lead to decreased TP53 
expression as seen by (B) qPCR and (C) Western blots. 
Figure 6: Caspase-3/7 activity was measured in miR-3151 and antagomiR-
3151 infected MM cell lines (MeWo, A375) compared to scramble control. miR-
3151 decreased caspase activity, while antagomiR-3151 increased caspase 
activity. 
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Figure 9: (A) BRAF was silenced in BRAFmut MM cell lines (A375, Mel-39) and miR-3151 
expression was determined compared to si-scramble control. (B) TP53 expression was 
measured in the BRAFmut cell lines after silencing BRAF compared to scramble control. 
(C) BRAFwt was overexpressed and the BRAF mutation was introduced in a BRAFwt cell 
line (MeWo), then miR-3151 expression and (D) TP53 expression were determined 
compared to empty vector. 
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Figure 7: The effect of antagomiR-3151 on the cell cycle in Mel-39 cells was 
examined by flow cytometry. The number of cells in S and G2 phases were reduced in 
the antagomiR-3151 infected cells compared to scramble control, suggesting that 
antogmiR-3151 reduces cell proliferation of MM cells. 
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Figure 3: Effects of miR-3151 on TP53 expression: MM cell lines were infected with 
the miR-3151 virus and RNA and protein were harvested to determine TP53 
expression. 
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Figure 4: (A) We 
silenced BRAF in 
BRAFmut MM cell lines 
and then determined 
miR-3151 and TP53 
expression. (B) We 
overexpressed BRAF 
wild-type and introduced 
the BRAF mutation in 
BRAFwt MM cell line. 
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Figure 1: microRNAs bind to the complementary sequence in the 3’ UTR of their target 
gene to downregulate gene expression via various mechanisms. 
Figure 2: miR-3151 deregulates TP53. Normally, TP53 activates caspases, which 
promote programed cell death (apoptosis). miR-3151 suppresses TP53, leading to 
decreased caspase activity, and reduced apoptosis. 
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